Advertisement

Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome

  • Ronald H. Goldschmidt

Abstract

Care for patients with human immunodeficiency virus (HIV) infection requires excellence in all aspects of family practice. The family physician’s roles include providing patient education to prevent uninfected persons from becoming infected, identifying and counseling infected persons, delivering comprehensive medical care (including antiretroviral treatment), prophylaxis against opportunistic infections, management of the acquired immunodeficiency syndrome (AIDS), and providing support and care for the family. New manifestations of HIV disease, diagnostic protocols, and drug recommendations for HIV disease1 change on a regular basis. Epidemiologic, social, and community trends also have important effects on clinical care.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Pneumocystis Carinii Pneumonia Cryptococcal Meningitis Mycobacterium Avium Complex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goldschmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions—1997. J Am Board Fam Pract 1997;10:144–67.PubMedGoogle Scholar
  2. 2.
    Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41 RR-17:1–19.Google Scholar
  3. 3.
    Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39 RR-1:1–14.Google Scholar
  4. 4.
    Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468–72.Google Scholar
  5. 5.
    Centers for Disease Control. Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. MMWR 1987;36:509–15.Google Scholar
  6. 6.
    Goldschmidt RH, Legg JJ. Counseling patients about HIV test results. J Am Board Fam Pract 1991;4:361–3.PubMedGoogle Scholar
  7. 7.
    Centers for Disease Control. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR 1989;38:236–8, 243–50.Google Scholar
  8. 8.
    Centers for Disease Control. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR 1991;40 RR-5:27–33.Google Scholar
  9. 9.
    Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. International AIDS Society—USA. JAMA 1996;276:146–54.PubMedCrossRefGoogle Scholar
  10. 10.
    BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086–92.CrossRefGoogle Scholar
  11. 11.
    Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44 RR-8:1–34.Google Scholar
  12. 12.
    Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:329–37.PubMedCrossRefGoogle Scholar
  13. 13.
    Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1332–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Berger TG, Obuch ML, Goldschmidt RH. Dermatologic manifestations of HIV infection. Am Fam Physician 1990; 41:1729–42.PubMedGoogle Scholar
  15. 15.
    Cohen PR, Grossman ME. Recognizing skin lesions of systemic fungal infections in patients with AIDS. Am Fam Physician 1994;49:1627–34.PubMedGoogle Scholar
  16. 16.
    Holland GN, Tufail A. New therapies for cytomegalovirus retinitis. N Engl J Med 1995;333:658–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Glatt AE, Anand A. Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Clin Infect Dis 1995;21:415–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Miller R. HIV-associated respiratory disease. Lancet 1996; 348:307–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med 1992;327:1853–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: the National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis carinii pneumonia. N Engl J Med 1990;323:1500–4.CrossRefGoogle Scholar
  21. 21.
    Centers for Disease Control. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993;42 RR-7:1–8.Google Scholar
  22. 22.
    Legg JJ. Women and HIV. J Am Board Fam Pract 1993;6:367–77.PubMedGoogle Scholar
  23. 23.
    Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994;121:769–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Newton HB. Common neurologic complications of HIV-1 infection and AIDS. Am Fam Physician 1995;51:387–98.PubMedGoogle Scholar
  25. 25.
    Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1993;329:995–1000.PubMedCrossRefGoogle Scholar
  27. 27.
    Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43 RR-11:1–20.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Ronald H. Goldschmidt

There are no affiliations available

Personalised recommendations